Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism Aurora A inhibitors(Serine/threonine-protein kinase Aurora-A inhibitors), FLT3 inhibitors(Tyrosine-protein kinase receptor FLT3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC22H23Cl2N7 |
InChIKeyAKJBLKUZXRMECW-UHFFFAOYSA-N |
CAS Registry1402709-93-6 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Myeloid Leukemia | Preclinical | GB | 26 Aug 2021 |